📰 Merck Sharp News
Page 42 - Merck Sharp News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Merck Sharp. Real-time updates on events, politics, business and more.
March 30, 2023
Researchers are comparing standard care with tucatinib plus trastuzumab and chemotherapy as first-line treatment in HER2+ unresectable/metastatic CRC.
March 30, 2023
Neoadjuvant nivolumab plus chemotherapy produced a long-term event-free survival benefit vs chemotherapy alone in patients with resectable non–small cell lung cancer, independent of whether patients underwent minimally invasive surgery or thoracotomy or complete or partial resection of the lung.
March 29, 2023
It is the first new treatment in 14 years approved to treat advanced cervical cancer.
March 29, 2023
The Pharmaceutical Journal from the Royal Pharmaceutical Society
March 28, 2023
/PRNewswire/ -- BJ Bioscience, Inc. BJ Bioscience, a biotech company focusing on discovery and development of novel biologics for cancer immunotherapy, today...
March 28, 2023
– Infinity ended 2022 with total cash and cash equivalents of $38.3 million – – Infinity Previously Announced Definitive Merger Agreement with MEI Pharma to Advance Three Promising... | March 28, 2023
March 28, 2023
Researchers have characterized common adverse reactions to combination lenvatinib and pembrolizumab in patients with advanced RCC.
March 28, 2023
It is the first new treatment in 14 years approved to treat advanced cervical cancer.
March 28, 2023
It is the first new treatment in 14 years approved to treat advanced cervical cancer.
March 28, 2023
It is the first new treatment in 14 years approved to treat advanced cervical cancer.